Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Thoracic 4Genitourinary 4Gastrointestinal 3Plasma cell 2Other solid neoplasm 2Myeloid 2Gynecologic 2Breast 2Endocrine 1Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Prostatic Neoplasms 1Mesothelioma 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Small Cell 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Electrocardiography × Thoracic × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 11 charts
EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

NCT04840615 2024-02-02

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
2 enrolled 14 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡